| Species |
Mouse |
| Protein Construction |
TPO (Ser22-Thr356)
Accession # P40226 |
|
| Purity |
> 95% as analyzed by SDS-PAGE |
| Endotoxin Level |
< 0.2 EU/μg of protein by gel clotting method |
| Biological Activity |
ED50 < 2.0 ng /ml, measured in a proliferation assay using MO7e cells. |
| Expression System |
HEK 293 Cells |
| Apparent Molecular Weight |
30~80 kDa, on SDS-PAGE under reducing conditions. |
| Formulation |
Lyophilized after extensive dialysis against PBS. |
| Reconstitution |
It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH₂O or PBS up to 100 μg/ml. |
| Storage & Stability |
Upon receiving, this product remains stable for up to 6 months at lower than -70°C. Upon reconstitution, the product should be stable for up to 1 week at 4°C or up to 3 months at -20°C. For long term storage it is recommended that a carrier protein (example 0.1% BSA) be added. Avoid repeated freeze-thaw cycles. |
| Target Background |
Thrombopoietin (TPO), also known as C-mpl ligand, MGDF and Thpo, is a glycoprotein hormone belonging to the EPO/TPO family. It is expressed mainly in the liver, kidney and skeletal muscle. TPO binds and signals through MLP/C_MPL receptor. It stimulates the proliferation and maturation of megakaryocytes from their committed progenitor cells, and it regulates the production and circulation of platelets. TPO has also been reported to promote the apoptosis of hypoxia-sensitized neurons and to inhibit neuronal differentiation. |
| Synonyms |
Thrombopoietin; C-mpl ligand; Megakaryocyte colony-stimulating factor; Megakaryocyte growthand development factor; Myeloproliferative leukemia virus oncogene ligand; THPO; MGDF; MKCSF; ML; MPLLG; THCYT1; TPO |
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.
